PFE at a glance
Pfizer Inc (PFE, SEC CIK 78003) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Pfizer Inc (PFE) reported revenue of $62.6 billion (down 1.6% from FY2024) and net income of $7.8 billion. Diluted EPS was $1.36.
- As of June 30, 2026, 69 institutional investment managers tracked by SignalX reported holding Pfizer Inc (PFE) shares worth $46.1 billion in 13F-HR filings.
- In the last 90 days, PFE insiders reported 3 open-market purchases ($3.0M) and 1 open-market sale ($83K) on Form 4, a net purchase of $2.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $62.6B
- −1.6% vs prior year
- Insiders · 90 days
- 3 buys · 1 sell
- Net +$2.9M
- 13F holders
- 69 funds
- $46.1B · +3 vs prior quarter
- Latest 8-K
- Aug 4, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Global pharma innovator generating 65% of revenues from 12 products >$1B each; Eliquis alone = 13% of total revenues in 2025
- Chantix returned to U.S. market in 2025 after 2021 recall; Oxbryta voluntarily withdrawn globally following negative benefit-risk assessment
- Voluntary MFN Agreement signed with Trump Administration in September 2025: three-year Section 232 tariff exemption contingent on increased U.S. manufacturing investment
- 41% of 2025 revenues from international operations (21% Europe, 12% China/Japan/Asia Pacific); intense generic competition in China cited as ongoing pressure
- OBBBA passed July 4, 2025 estimated to raise U.S. uninsured population by 10 million, directly threatening product demand
Risk Factors
- IRA Medicare Drug Price Negotiation Program: Eliquis, Ibrance, Xtandi, and Xeljanz selected for Maximum Fair Price; IRA Part D Redesign already hit 2025 revenues ~$1B
- OBBBA (enacted July 4, 2025) cuts Medicaid/ACA funding; CBO estimates 10M more uninsured, threatening product demand and pricing
- Revenue concentration risk: 12 products = 65% of total revenues in 2025; Eliquis alone = 13%, with patent expiry and IRA Maximum Fair Price effective January 1, 2026
- China VBP/QCE generic competition intensifying; China = 5% of total revenues with accelerating price cuts on off-patent products
- MFN Agreement with Trump Administration: discounts up to 85% on TrumpRx.gov platform, average ~50%, with binding final terms still being negotiated
Management Discussion & Analysis
- Revenue $62.2B in 2025, up ~$0.7B (~1%) YoY from $63.6B in 2024; international ops $25.5B (41% of total)
- IRA Medicare Part D Redesign negatively impacted 2025 revenues by ~$1B; Eliquis alone = 13% of total revenues
- Oncology (Seagen-driven ADCs: Padcev, Adcetris, Tivdak) best-performing growth area; COVID products (Comirnaty, Paxlovid) continued multi-year revenue decline
- Capex included ~$125M environment-related; ~$500M R&D savings from cost-base realignment program to be reinvested in R&D in 2026; Metsera acquired November 2025
- Key risks: patent cliff 2026–2030 accelerating, MFN/TrumpRx pricing agreement with U.S. government, tariff exposure (3-year Section 232 grace period secured), IRA MDPNP expanding to Ibrance and Xtandi effective 2027
AI summary of the PFE 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 28, 2026
Management Discussion & Analysis
- MD&A excerpt contains no quarterly revenue, profitability, segment, cash-flow, or outlook figures
Risk Factors
- No risk-factors section provided; excerpt begins with Item 2 and does not state whether risks materially changed
- Restructuring execution risk: additional Realigning Our Cost Base savings of $1 billion require approximately $2 billion in costs through 2029
- Manufacturing disruption risk: next optimization phase targets $1.5 billion savings with approximately $4.0 billion implementation costs through 2029
- Financial cost risk: manufacturing program costs comprise approximately 60% non-cash expenditures and 40% cash expenditures
- Forecast risk: restructuring savings, costs, timing, and potential additional charges remain subject to assumptions and may differ from expectations
AI summary of the PFE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Pfizer reported second-quarter 2026 financial results on August 4, 2026
- Detailed revenue, earnings and outlook figures are contained in Exhibit 99
Item EX-99.1: Item EX-99.1
- Q2 revenue $15.034B, up 3%; operational growth 1%, excluding Comirnaty and Paxlovid growth reached 5%
- Launched and acquired products grew 18% operationally, led by Eliquis 19%, Padcev 23%, Vyndaqel 8%, and Lorbrena 37%
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CFO Dave Denton departing August 15, 2026 for consumer-goods opportunity outside pharmaceuticals
- Departure explicitly unrelated to Pfizer’s financial results, operations, or accounting disagreements
Item 7.01: Regulation FD Disclosure
- 2026 guidance reaffirmed after CFO transition, signaling no immediate change to operating or financial outlook
- Revenue guidance maintained at $59.5–$62.5 billion
AI summaries of PFE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PFE
Don't miss the next PFE filing
- Alerts as it files. A push when PFE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PFE, by share count.
- Ask anything. An AI agent that reads every PFE filing and answers with sources.
PFE alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| BOURLA ALBERT | A | Sep 30, 2026 | 21 | $28.52 |
| Taraporevala Cyrus | A | Sep 25, 2026 | 1,307.987 | $28.67 |
| Echevarria Joseph | A | Sep 25, 2026 | 1,613.185 | $28.67 |
| NARAYEN SHANTANU | A | Sep 25, 2026 | 1,743.983 | $28.67 |
| SMITH JAMES C | A | Sep 25, 2026 | 1,569.585 | $28.67 |
| Quincey James | A | Sep 25, 2026 | 1,351.587 | $28.67 |
| Buckley Mortimer J | A | Sep 25, 2026 | 1,307.987 | $28.67 |
| BOURLA ALBERT | A | Sep 15, 2026 | 22 | $27.55 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $58.5B | $63.6B | $62.6B |
| Net Income | $2.1B | $8.0B | $7.8B |
| Net Margin | 3.6% | 12.6% | 12.4% |
| Balance Sheet | |||
| Total Assets | - | $213.4B | $208.2B |
| Equity | $89.0B | $88.2B | $86.5B |
| ROE | 2.4% | 9.1% | 9.0% |
| Per Share | |||
| EPS | $0.37 | $1.41 | $1.36 |
| Cash Flow | |||
| Operating CF | $8.7B | $12.7B | $11.7B |
| CapEx | $3.9B | $2.9B | $2.6B |
Source: XBRL data in Pfizer Inc (PFE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate PFE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 69 | $46.06B |
| Q1 2026 | 66 | $52.58B |
| Q4 2025 | 64 | $47.42B |
| Q3 2025 | 69 | $49.47B |
| Q2 2025 | 67 | $46.34B |
| Q1 2025 | 66 | $35.50B |
| Q4 2024 | 62 | $31.62B |
| Q3 2024 | 55 | $18.51B |
- BlackRock+31.41M (+6%)
- AQR Capital Management+6.68M (+56%)
- Goldman Sachs Group+5.89M (+12%)
- State Street Corp+5.50M (+2%)
- BNY Mellon+4.00M (+7%)
- Franklin Resources−10.54M (-37%)
- D.E. Shaw & Co−7.05M (-57%)
- Ameriprise Financial−5.15M (-26%)
- JPMorgan Chase & Co−4.88M (-18%)
- Bank of America Corp−2.96M (-6%)
- W. R. Berkley Corporation+965.5K
- Bridgewater Associates LP+180.1K
- WESTWOOD HOLDINGS GROUP INC+25.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 518 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PFE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 13F-HR | Aug 13, 2026 | Jun 30, 2026 | - | |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 10-Q | Aug 4, 2026 | Jun 28, 2026 | Analysis | |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jul 13, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
PFE SEC filings: frequently asked questions
Are PFE insiders buying or selling?
In the last 90 days, Pfizer Inc (PFE) officers, directors and 10% owners reported 3 open-market purchases worth $3.0 million by 3 insiders and 1 open-market sale worth $83,261 by 1 insider on Form 4, a net purchase of $2.9 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PFE stock?
As of June 30, 2026, the largest Pfizer Inc (PFE) holders among the 13F filers tracked by SignalX were BlackRock ($12.8 billion), Vanguard Capital Management LLC ($9.0 billion), State Street Corp ($7.4 billion), Vanguard Portfolio Management LLC ($2.9 billion), Morgan Stanley ($2.3 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PFE's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Pfizer Inc (PFE) reported revenue of $62.6 billion (down 1.6% from FY2024) and net income of $7.8 billion. Diluted EPS was $1.36. The figures come from the XBRL data in the 10-K.
What are the main risks in PFE's latest 10-K?
In the 10-K filed February 26, 2026, Pfizer Inc (PFE) flagged: IRA Medicare Drug Price Negotiation Program: Eliquis, Ibrance, Xtandi, and Xeljanz selected for Maximum Fair Price; IRA Part D Redesign already hit 2025 revenues ~$1B. OBBBA (enacted July 4, 2025) cuts Medicaid/ACA funding; CBO estimates 10M more uninsured, threatening product demand and pricing. (AI summary of the Risk Factors section.)
What did PFE report in its latest 8-K?
Pfizer Inc (PFE) filed an 8-K on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Pfizer reported second-quarter 2026 financial results on August 4, 2026.
What are the latest PFE SEC filings?
Pfizer Inc (PFE) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and a Form 4 insider filing on October 1, 2026.
What is PFE's SEC CIK number?
Pfizer Inc (PFE)'s SEC Central Index Key (CIK) is 78003. EDGAR lists every PFE filing under that number.
Ask anything about PFE
The research agent reads PFE's filings, financials, insider trades and 13F holders, then answers with sources.